A rapid, specific, and sensitive method for the determination of acetylation phenotype using dapsone

Journal of Analytical Toxicology

Volumn 21, Issue 3, 1997, Pages 203-207

  Queiroz, R H C ^a   Dreossi, S A C ^a   Carvalho, D ^a,b  

^a Depto Anal Clin Toxicol/B   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; ACYLTRANSFERASE; DAPSONE; METHANOL; PHENACETIN;

ACETYLATOR PHENOTYPE; ARTICLE; BRAZIL; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; TABLET;

EID: 0031020405     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/21.3.203     Document Type: Article

References (16)

1. A. Vadher and M. Lalljee. Patient treatment compliance in leprosy - A critical review. Int. J. Lepr. 60: 587-607 (1992).
2. M.D. Edstein, K.H. Riechmann, and J.R. Veenendaal. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim®) in man. Br. J. Clin. Pharmacol. 30: 259-65 (1990).
3. P. Pertel and R. Hirschtick. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 18: 630-32 (1994).
4. B.L. Erstad. Dapsone induced methemoglobinemia and hemolytic anemia. Clin. Pharm. 11: 800-805 (1992).
5. S.R. Byrd and R.H. Gibber. Effect of dapsone haemoglin concentration in patients with leprosy. Lepr. Rev. 62: 71-78 (1991).
6. Y.M. Irshaid, H.F. Al-Hadidi, M.A. Abuirjeie, and N.M. Rawashdeh. N-Acetylation phenotyping using dapsone in a Jordanian population. Br. J. Clin. Pharmac. 32: 289-93 (1991).
7. M.M. Reidenberg, D.E. Drayer, B. Lorenzo, B.L. Strom, S.L. West, E.S. Snyder, B. Freundlich, and P.D. Stolley. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum. 36: 971-73 (1993).
8. R.B. Hayes, W. Bi, N. Rothman, F. Broly, N. Caporaso, P. Feng, X. You, S. Yin, R.L. Woosley, and U.A. Meyer. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14: 675-78 (1993).
9. Y. Horai and T. Ishizaki. N-Acetylation polymorphism of dapsone in a Japanese population. Br. J. Clin. Pharmacol. 25: 487-94 (1988).
10. P.A. Philip, M.S. Roberts, and H.J. Rogers. A rapid method for determination of acetylation phonotype using dapsone. Br. J. Clin. Pharmacol. 17: 465-69 (1984).
11. R. Gelber, J.H. Peters, G.R. Gordon, A.J. Glazko, and L. Levy. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. Ther. 12: 225-38 (1971).
12. M. Edstein. Simultaneous measurement of dapsone, monoacetyldapsone and pyrimethamine in human plasma. J. Chromatogr. 307: 426-31 (1984).
13. N.L. Pochopin, W.N. Charman, and V.J. Stella. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab. Dispos. 22: 770-75 (1994).
14. A.M. Roon, M.M. Lemnge, H.R. Angels, and I.C. Bygbjerb. High-performance liquid chromatography determination of dapsone, monoacetyldapsone and pyrimethamine in filter paper blood spots. Ther. Drug Monit. 17: 79-83 (1995).
15. J. Moncrieff. Determination of dapsone in serum and saliva using reversed-phase high-performance liquid chromatography with ultraviolet or electrochemical detection. J. Chromatogr. B. 654: 103-10 (1994).
16. P.S. Bonato and V.L. Lanchote. A rapid procedure for the purification of biological samples to be analyzed by high performance liquid chromatography. J. Liq. Chromatogr. 16: 2299-2308 (1993).